Exposure-response relationship of the synthetic epothilone sagopilone in a peripheral neurotoxicity rat model

Neurotoxicity Research

Volumn 22, Issue 2, 2012, Pages 91-101

  Chiorazzi, Alessia ^a   Höchel, Joachim ^b   Stöckigt, Detlef ^b   Canta, Annalisa ^a   Carozzi, Valentina Alda ^a   Meregalli, Cristina ^a   Avezza, Federica ^a   Crippa, Luca ^a   Sala, Barbara ^a   Ceresa, Cecilia ^a   Oggioni, Norberto ^a   Cavaletti, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Bayer Schering Pharma   (Germany)

Author keywords

Peripheral neuropathy; Pharmacodynamics; Pharmacokinetic; Rat; Sagopilone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; SAGOPILONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DEGRADATION; DRUG TISSUE LEVEL; FEMALE; KIDNEY; LEUKOCYTE COUNT; LIVER; MAXIMUM PLASMA CONCENTRATION; NERVE CONDUCTION; NERVOUS TISSUE; NEUROPHYSIOLOGY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SCIATIC NERVE; TANDEM MASS SPECTROMETRY;

ANIMALS; AREA UNDER CURVE; BENZOTHIAZOLES; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; DATA INTERPRETATION, STATISTICAL; EPOTHILONES; FEMALE; INFUSIONS, INTRAVENOUS; KIDNEY; LIVER; NEURAL CONDUCTION; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, WISTAR; SCIATIC NERVE;

RATTUS; RATTUS NORVEGICUS;

EID: 84865349109     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-011-9302-7     Document Type: Article

References (30)

1. Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S et al (2009) Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 101:1241-1247
2. Attard G, Greystoke A, Kaye S, De Bono J (2006) Update on tubulin-binding agents. Pathol Biol (Paris) 54:72-84
3. Canta A, Chiorazzi A, Cavaletti G (2009) Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 16:1315-1324
4. Canta A, Meregalli C, Chiorazzi A, Carozzi VA, Crippa L, Marmiroli P et al (2010) The ventral caudal nerve: a physiologic-morphometric study in three different rat strains. J Peripher Nerv Syst 15:140-146
5. Canta A, Chiorazzi A, Carozzi V, Meregalli C, Oggioni N, Sala B et al (2011) In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin). Cancer Chemo-ther Pharmacol 68(4):1001-1008
6. Cardoso F, de Azambuja E, Lago LD (2008) Current perspectives of epothilones in breast cancer. Eur J Cancer 44:341-352
7. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D (1992) Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl) 84:364-371
8. Cavaletti G, Minoia C, Schieppati M, Tredici G (1994) Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 29:771-776 (Pubitemid 24241317)
9. Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12:271-280 (Pubitemid 46556793)
10. DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D et al (2010) Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer 103:1548-1553
11. Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann KH (2008) Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res 41:21-31
12. Fornier MN (2007) Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Cancer 7:757-763 (Pubitemid 350086120)
13. Fumoleau P, Coudert B, Isambert N, Ferrant E (2007) Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 18(Suppl 5):v9-v15
14. Galmarini CM (2009) Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr Opin Investig Drugs 10: 1359-1371
15. Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22:2015-2025 (Pubitemid 41095195)
16. Kolman A (2005) Activity of epothilones. Curr Opin Investig Drugs 6:616-622 (Pubitemid 40852296)
17. Larkin JM, Kaye SB (2006) Epothilones in the treatment of cancer. Expert Opin Investig Drugs 15:691-702
18. Lee JJ, Swain SM (2008) The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 14:1618-1624 (Pubitemid 351469445)
19. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A et al (2010) Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 14:343-350
20. Morris PG, Fornier MN (2009) Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer. Clin Adv Hematol Oncol 7:115-122
21. Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M et al (2010) Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Res Treat 123:837-842
22. Pronzato P (2008) New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones. Drugs 68: 139-146
23. Rustin G, Reed N, Jayson GC, Ledermann JA, Adams M, Perren T et al (2011) A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol 22:2411-2416
24. Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M et al (2010) Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 21:633-639
25. Silvani A, Gaviani P, Fiumani A, Scaioli V, Lamperti E, Eoli M et al (2009) Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 95:61-64
26. Strube A, Suominen MI, Rissanen JP, Mumberg D, Klar U, Halleen JM et al (2011) The anti-tumor agent sagopilone shows anti-resorptive effects both in vitro and in vivo. Osteoporos Int 22: 2887-2893
27. Stupp R, Tosoni A, Bromberg JE, Hau P, Campone M, Gijtenbeek J et al (2011) Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 22:2144-2149
28. Teicher BA (2008) Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 14:1610-1617 (Pubitemid 351469444)
29. Tredici G, Cavaletti G, Petruccioli MG, Fabbrica D, Tedeschi M, Venturino P (1994) Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology 15:701-704 (Pubitemid 24321266)
30. Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD (2008) Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol 4:483-500